Immunomodulatory Effects of Interferons in Malignancies
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Investigation of the antitumor and immunomodulatory activities of interferon (IFN) began shortly after the cytokine was discovered in 1957. Early work showed a direct correlation between administration of IFN and inhibition of symptoms associated with virally induced leukemia in mice as well as an increase in their survival time. Subsequent studies with purified IFNs confirmed the direct and indirect stimulation of immune cells, resulting in antitumor activities of IFN. Clinically, IFN-alphas (αs) have been shown to have activity against a variety of tumors. Initially, the U.S. Food and Drug Administration licensed 2 recombinant IFN-αs for the treatment of hairy-cell leukemia and then later for several other cancers. The success rate seen with IFNs and certain tumors has been varied. Unfortunately, some neoplasms show no response to IFN. Monocytes/macrophages play an important role in cancer progression. Monocytes in combination with IFN may be an important therapy for several cancers. This article focuses on the role of IFN and monocytes alone or in combination in affecting malignancies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Interferon-γ: an overview of signals, mechanisms and functions
Schroder, K., Hertzog, P. J., Ravasi, T., & Hume, D. A. (2004) · Journal of Leukocyte Biology · doi:10.1189/jlb.0603252 · Cited by 4,120
Virus interference. I. the interferon
Isaacs, A., & Lindenmann, J. (1957) · Proceedings of the Royal Society of London. Series B - Biological Sciences · doi:10.1098/rspb.1957.0048 · Cited by 3,451 · cited 1×
“I nterferon (IFN) was defined as an antiviral agent by Isaacs and Lindenmann (1957) and by Paucker and others (1962) for its antigrowth activity.”
Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis
Chawla-Sarkar, M., Lindner, D. J., Liu, Y.-F., Williams, B. R., Sen, G. C., Silverman, R. H., & Borden, E. C. (2003) · Apoptosis · doi:10.1023/a:1023668705040 · Cited by 829
Menon, C., Bauer, T. W., Kelley, S. T., Raz, D. J., Bleier, J. I., Patel, K., Steele, K., Prabakaran, I., Shifrin, A., Buerk, D. G., et al. (2008) · International Journal of Cancer · doi:10.1002/ijc.23499 · Cited by 11
Cited by
Recent advances in nanomaterial-based synergistic combination cancer immunotherapy
Sang, W., Zhang, Z., Dai, Y., & Chen, X. (2019) · Chemical Society Reviews · doi:10.1039/c8cs00896e · Cited by 405
Immunomodulatory activity of interferon‐beta
Kasper, L. H., & Reder, A. T. (2014) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.84 · Cited by 159
Eiró, N., Sendon-Lago, J., Seoane, S., Bermúdez, M. A., Lamelas, M. L., Garcia-Caballero, T., Schneider, J., Perez-Fernandez, R., & Vizoso, F. J. (2014) · Oncotarget · doi:10.18632/oncotarget.2530 · Cited by 92
Central Role of ULK1 in Type I Interferon Signaling
Saleiro, D., Mehrotra, S., Kroczynska, B., Beauchamp, E. M., Lisowski, P., Majchrzak-Kita, B., Bhagat, T. D., Stein, B. L., McMahon, B., Altman, J. K., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.03.056 · Cited by 74
Metadata
- Authors
- Bekisz, J., Sato, Y., Johnson, C., Husain, S. R., Puri, R. K., & Zoon, K. C.
- Venue
- Journal of Interferon & Cytokine Research
- Publisher
- SAGE Publications
- Published
- 2013-04
- Volume
- 33
- Issue
- 4
- Pages
- 154-161
- ISSN
- 1079-9907 (ISSN-L)
- 1557-7465
- OpenAlex
- W2041817127
- Cited by
- 49
- References
- 4
- FWCI
- 2.99
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Immunomodulatory Effects of Interferons in Malignancies. https://app.cochat.ai/papers/10.1089/jir.2012.0167
- The paper
- Bekisz, J., Sato, Y., Johnson, C., Husain, S. R., Puri, R. K., & Zoon, K. C. (2013). Immunomodulatory Effects of Interferons in Malignancies. Journal of Interferon & Cytokine Research. https://doi.org/10.1089/jir.2012.0167
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.